Composition for Preventing or Treating AIDS Containing Plant Stem Cell Line Derived from Cambium of Panax Ginseng Including Wild Ginseng or Ginseng as Active Ingredient

Abstract

The present invention relates to a composition for preventing or treating acquired immunodeficiency syndrome (AIDS), comprising one or more of the following: a homogenous cell line, and a lysate, an extract and a culture thereof as an active ingredient. The homogenous cell line, the lysate, the extract and the culture thereof, which are derived from a natural product, minimize adverse side effects of prior therapeutic agents and safe for the human body. Further, they effectively increase the count of T cells such as CD4+ T cells and decrease the number of HIVs, thereby preventing opportunistic infection, dysneuria, and neoplasia caused by immune incompetence, and ultimately the risk of death. Therefore, they are useful in preventing and treating AIDS, and relieving symptoms of AIDS.

Description

FIELD OF THE INVENTION[0001]The present invention relates to a composition for preventing or treating acquired immunodeficiency syndrome (AIDS), comprising one or more of the following: a cell line derived from the cambium of Panax ginseng including wild ginseng and ginseng, and a lysate, an extract and a culture thereof, as an active ingredient.BACKGROUND OF THE INVENTION[0002]Since an AIDS (acquired immunodeficiency syndrome) patient was first found in 1982, in Los Angeles, USA, the number of patients has increased worldwide. In Korea, AIDS patients have steadily increased from the discovery of an American AIDS patient in 1985, requiring the development of new therapeutic agents.[0003]Human immunodeficiency virus (HIV) is an enveloped virus that attacks mainly human lymphocytes, and belongs to a member of the retrovirus family as it converts its viral RNA genome to DNA by reverse transcription and integrates the resulting DNA into the cellular DNA of a host cell. HIV has RNA as it...

AI Technical Summary

Benefits of technology

"The present invention provides a natural product-derived compound for the prevention and treatment of acquired immunodeficiency syndrome (AIDS) with minimized adverse side effects compared to prior therapeutic agents. The invention includes a cell line, a lysate, an extract, and a culture thereof, which are derived from the cambium of Panax ginseng and have the following characteristics: an innately undifferentiated state, a homogeneous cell line, and multiple vacuoles. The invention also provides a functional food, an immune enhancing agent, and a method for preventing or treating AIDS by applying the cell line, lysate, extract, or culture thereof."

Problems solved by technology

The cell entry of HIV depends on gp120 which binds to intracellular CD4 receptor molecules, and HIV infection causes depletion of CD4+ T cells, thereby leading to immunological incompetence, opportunistic infection, dysneuria, neoplasia, and ultimately death.

Until now, several anti-HIV agents, including 2,3-azidothymidine (AZT), dideoxyinosine (ddI), dideoxycytidine (ddC), and others have been approved by FDA in the United States, but they failed to exhibit complete therapeutic effects without severe adverse side effects.

Thus, the development of novel medicaments has become the critical issue.

However, the agents have side effects such as diabetes, hemolysis, hemorrhage, hyperlipidemia, impaired lipid metabolism, and others, and causes serious problem of the emergence of tolerant cell lines due to the long-term administration.

Images